Pharmaxis Ltd (ASX:PXS)


right-arrow Created with Sketch. 0.003 (2.5%)
MCAP $53.57M
Last trade 13.33pm 07/12/2021 20mins delayed

Latest Announcements

02/12/2021PXSPharmaxis Ltd
30/11/2021PXSPharmaxis Ltd
25/11/2021 Price SensitivePSPXSPharmaxis Ltd
24/11/2021PXSPharmaxis Ltd
24/11/2021PXSPharmaxis Ltd
23/11/2021PXSPharmaxis Ltd
18/11/2021PXSPharmaxis Ltd
17/11/2021 Price SensitivePSPXSPharmaxis Ltd

Company Overview

Pharmaxis Ltd is a clinical stage drug development company engaged in developing drugs for inflammatory and fibrotic diseases and focused on myelofibrosis. The Company has two approved respiratory products, Bronchitol and Aridol. The Bronchitol is used for the treatment of cystic fibrosis to help patient’s clear mucus from their lungs. Aridol is a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness. The Company's development pipeline assets include a topical pan-Lysyl Oxidase (LOX) inhibitor in development for scar revision, keloid scarring and scarring from burn wounds; a series of Lysyl Oxidase Like 2 (LOXL2) inhibitors targeting fibrotic diseases of the kidney, lung, liver, and heart; and an anti-inflammatory dual Semicarbazide-Sensitive Amine Oxidase (SSAO)/ Monoamine oxidase B (MAOB) inhibitor targeting Duchenne Muscular Dystrophy.

PXS in the news

Clinical stage drug development company Pharmaxis (PXS) has opened a $2 million share purchase…
Pharmaxis (PXS) grants Aptar Pharma the exclusive option to acquire worldwide rights…
Pharmaxis (PXS) reports encouraging results from studies of its anti-cancer drug in…
The first dose level of Pharmaxis’ (PXS) PXS-5505 drug shows strong inhibition…

Search Previous Announcements